Table 2.
Information of pathway enrichment analysis of genes in significant modules corresponding to Figure 4A–D
| Pathway term | Count | p-value | Genes | |
|---|---|---|---|---|
| A | hsa04110: Cell cycle | 4 | 2.25E–05 | MAD2L1, BUB1, BUB1B, CDC20 |
| hsa04114: Oocyte meiosis | 3 | 1.46E–03 | MAD2L1, BUB1, CDC20 | |
| hsa05166: Human T-cell leukemia virus type 1 infection | 3 | 7.79E–03 | MAD2L1, BUB1B, CDC20 | |
| hsa04914: Progesterone-mediated oocyte maturation | 2 | 4.96E–02 | MAD2L1, BUB1 | |
| B | hsa04080: Neuroactive ligand–receptor interaction | 5 | 1.57E–04 | GRM3, GRM2, SSTR1, OPRK1, CNR1 |
| hsa04724: Glutamatergic synapse | 4 | 2.32E–04 | GRM3, ADCY2, GRM2, ADCY8 | |
| hsa04024: Cyclic adenosine monophosphate signaling pathway | 4 | 1.16E–03 | ADCY2, NPY, SSTR1, ADCY8 | |
| hsa04923: Regulation of lipolysis in adipocytes | 3 | 1.76E–03 | ADCY2, NPY, ADCY8 | |
| hsa04971: Gastric acid secretion | 3 | 2.97E–03 | ADCY2, ADCY8, SST | |
| hsa04723: Retrograde endocannabinoid signaling | 3 | 5.20E–03 | ADCY2, ADCY8, CNR1 | |
| hsa04015: Rap1 signaling pathway | 3 | 2.29E–02 | ADCY2, ADCY8, CNR1 | |
| C | hsa04260: Cardiac muscle contraction | 6 | 7.29E–09 | MYL2, MYL3, TNNC1, MYH6, TPM2, TPM1 |
| hsa05410: Hypertrophic cardiomyopathy | 6 | 8.90E–09 | DES, MYL2, MYL3, TNNC1, TPM2, TPM1 | |
| hsa05414: Dilated cardiomyopathy | 6 | 1.30E–08 | DES, MYL2, MYL3, TNNC1, TPM2, TPM1 | |
| hsa04261: Adrenergic signaling in cardiomyocytes | 6 | 2.12E–07 | MYL2, MYL3, TNNC1, MYH6, TPM2, TPM1 | |
| hsa04530: Tight junction | 3 | 7.00E–03 | MYL2, ACTN2, MYH6 | |
| D | hsa04110: Cell cycle | 6 | 1.03E–08 | MAD2L1, BUB1, BUB1B, CDC20, SMC3, STAG2 |
| hsa04114: Oocyte meiosis | 4 | 7.44E–05 | MAD2L1, BUB1, CDC20, SMC3 | |
| hsa05166: HTLV-I infection | 3 | 1.85E–02 | MAD2L1, BUB1B, CDC20 |
Note: A, B, C, and D correspond to the modules in Figure 4.